Prevention of thromboembolic complications in patients with end-stage kidney disease and atrial fibrillation


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

End-stage kidney disease has a high risk of thromboembolic complications, which is further exacerbated by the addition of atrial fibrillation. The comorbidity of these pathologies presents a unique problem due to the combination of increased risk of stroke and bleeding. when prescribing anticoagulants, treatment adherence and persistence are low, thus, many patients are not receiving treatment. newer oral anticoagulants may offer an alternative to a vitamin k antagonist in patients with end-stage kidney disease, but these drugs have not been extensively studied in this population, and therefore, uncertainty about comparative efficacy remains. In this review, we discuss current data on the risks and benefits of anticoagulants in this challenging setting.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Sherzod Abdullaev

Tashkent Pediatric Medical Institute; Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation

Email: sherzod.abdullaev83@gmail.com
Dr. Sci. (Med.), Associate Professor at the Department of Internal Medicine, Nephrology and Hemodialysis, Tashkent Pediatric Medical Institute; Head of the Department of Immunogenetics, Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation Tashkent, Uzbekistan

Ranokhon Igamberdieva

Tashkent Pediatric Medical Institute

Email: rano1982@yandex.ru
Teaching Assistant at the Department of Internal Medicine, Nephrology and Hemodialysis Tashkent, Uzbekistan

Әдебиет тізімі

  1. Kuno T., Takagi H., Ando T., Sugiyama T., Miyashita S,. Valentin N., Shimada Y.J., Kodaira M., Numasawa Y., Briasoulis A., Burger A., Bangalore S. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am Coll Cardiol. 2020 Jan 28;75(3):273-85. doi: 10.1016/j.jacc.2019.10.059.
  2. Van Zyl M.; Abdullah H.M.; Noseworthy P.A.; Siontis K.C. Stroke Prophylaxis in Patients with Atrial Fibrillation and End-Stage Renal Disease. J. Clin. Med. 2020, 9, 123. https://doi.org/10.3390/jcm9010123
  3. Lin Y.C., Chen B.L., Shih C.M., Lin F.Y., Chen C.W., Hsu C.Y., Kao Y.T., Bi W.F., Chen L.Y., Chien L.N., Fang T.C., Huang C.Y. Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study. PLoS One. 2021 Apr 8;16(4):e0249940. doi: 10.1371/journal.pone.0249940.
  4. Agarwal M.A., Potukuchi P.K., Sumida K., Naseer A., Molnar M.Z., George L.K., Koshy S.K., Streja E., Thomas F., Kalantar-Zadeh K., Kovesdy C.P Clinical Outcomes of Warfarin Initiation in Advanced Chronic Kidney Disease Patients With Incident Atrial Fibrillation. JACC Clin Electrophysiol. 2020Dec 14;6(13):1658-68. doi: 10.1016/j.jacep.2020.06.036.
  5. Randhawa M.S., Vishwanath R., Rai M.P., Wang L., Randhawa A.K., Abela G., Dhar G. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Apr 1;3(4):e202175. doi: 10.1001/jamanetworkopen.2020.2175.
  6. Waddy S.P., Solomon A.J., Becerra A.Z., Ward J.B., Chan K.E., Fwu C.W., Norton J.M., Eggers P.W., Abbott K.C., Kimmel P.L. Racial/Ethnic Disparities in Atrial Fibrillation Treatment and Outcomes among Dialysis Patients in the United States. J Am Soc Nephrol. 2020 Mar;31(3):637-49. doi: 10.1681/ASN.2019050543. Epub 2020 Feb 20.
  7. Nochaiwong S., Ruengorn C., Awiphan R., Dandecha P., Noppakun K., Phrommintikul A. Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: A systematic review and meta-analysis. Open Heart 2016, 3, e000441. doi: 10.1136/openhrt-2016-000441. eCollection 2016.
  8. Lee M., Saver J.L., Hong K.S., Wu Y.L., Huang W.H., Rao N.M., Ovbiagele B. Warfarin Use and Risk of Stroke in Patients With Atrial Fibrillation Undergoing Hemodialysis A Meta-Analysis. Medicine 2016:95. doi: 10.1097/MD.0000000000002741.
  9. Shen J.I., Montez-Rath M.E., Lenihan C.R., Turakhia, M.P., Chang, T.I., Winkelmayer W.C. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. Am. J. Kidney Dis. 2015, Oct;66(4):677-688. doi: 10.1053/j.ajkd.2015.05.019.
  10. Dahal K., Kunwar S., Rijal J., Schulman P., Lee J. Stroke, Major Bleeding and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. Chest 2016, 149, 951-959. Doi.org/10.1378/chest.15-1719
  11. Tan J.W., Liu S.Q., Segal J.B., Alexander G.C., McAdams-DeMarco M. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: A systematic review and metaanalysis. BMC Nephrol. 2016;17:157.
  12. Liu G., Long M., Hu X., Hu C.H., Liao X.X., Du Z.M., Dong Y.G. Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation A Meta-Analysis of Observational Studies. Medicine 2015;94.
  13. Van Der Meersch H.; De Bacquer D., De Vriese A.S. Vitamin Kantagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Am. Heart J. 2017;184:37-46.
  14. Chan P.H., Huang D., Yip P.S., Hai J., Tse H.F., Chan T.M., Lip G.Y., Lo W.K., Siu C.W. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace 2016; 18:665- 71.
  15. Nigwekar S.U., Zhao S., Wenger J., Hymes J.L., Maddux F.W., Thadhani R.I., Chan K.E. A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors. J. Am. Soc. Nephrol. 2016;27:3421-29.
  16. Santos P.W., He J., Tuffaha A., Wetmore J.B. Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy.Int. Urol. Nephrol. 2017;49:2247-56.
  17. Yao X., Tangri N., Gersh B.J., Sangaralingham L.R., Shah N.D., Nath, K.A., Noseworthy P.A. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J. Am. Coll. Cardiol. 2017;70:2621-32.
  18. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M., Diener H.C., Heidbuchei H., Hendriks J. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. J. Cardio Thorac. Surg. Off. J. Eur. Assoc. Cardio Thorac. Surg. 2016;50:e1-e88.
  19. Dangas G.D., Tijssen J.G.P., Wohrle J., Sondergaard L., Gilard M., Mollmann H., Makkar R.R., Herrmann H.C., Giustino G., Baldus S. et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. N. Engl. J. Med. 2019.
  20. Lutz J., Jurk, K., Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: Patient selection and special considerations.Int. J. Nephrol. Renov. Dis. 2017;10:135-43.
  21. Wang X., Tirucherai G., Marbury T.C., Wang J., Chang M., Zhang D., Song Y., Pursley J., Boyd R.A., Frost C. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J. Clin. Pharmacol. 2016;56:628-36.
  22. Chang M., Yu Z., Shenker A., Wang J., Pursley J., Byon W., Boyd R.A., LaCreta F., Frost C.E. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J. Clin. Pharmacol. 2016; 56:637-45.
  23. Yao X.; Shah N.D.; Sangaralingham L.R.; Gersh B.J., Noseworthy P.A. Non-Vitamin KAntagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J. Am. Coll. Cardiol. 2017;69;2779-90.
  24. Mavrakanas T.A., Samer C.F., Nessim S.J., Frisch G., Lipman M.L. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. J. Am. Soc. Nephrol 2017;28:2241-48].
  25. Stanton B.E., Barasch N.S., Tellor K.B.Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy. 2017;37:412-19.
  26. Sarratt S.C., Nesbit R., Moye R. Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease. Ann. Pharmacother. 2017; 51:445-50.
  27. So C.Y., Cheung G.S.H., Chan C.K.Y., Kam K.K.H., Chan A.K.Y., Au S.S.W., Chan S.K.C., Lam Y.Y., Lee A.P.W., Yan B.P.Y. Effect of Chronic Kidney Disease on Left Atrial Appendage Occlusion Outcome: A Single-Centre Retrospective Analysis. J. Am. Coll. Cardiol. 2018;71:302.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>